1.	Amor, B., Yaliraki, S. N., Woscholski, R., & Barahona, M. (2014). Uncovering allosteric pathways in caspase-1 with Markov transient analysis and multiscale community detection. In arXiv.org (p. n). https://doi.org/10.1039/c4mb00088a
2.	Asante, E. A., Smidak, M., Grimshaw, A., Houghton, R., Tomlinson, A., Jeelani, A., Jakubcova, T., Hamdan, S., Richard-Londt, A., Linehan, J. M., Brandner, S., Alpers, M., Whitfield, J., Mead, S., Wadsworth, J. D. F., & Collinge, J. (2015). A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 522(7557), 478–481F. https://doi.org/10.1038/nature14510
3.	Babinsky, V. N., Hannan, F. M., Gorvin, C. M., Howles, S. A., Nesbit, M. A., Rust, N., Hanyaloglu, A. C., Hu, J., Spiegel, A. M., & Thakker, R. V. (2016). Allosteric Modulation of the Calcium-sensing Receptor Rectifies Signaling Abnormalities Associated with G-protein α-11 Mutations Causing Hypercalcemic and Hypocalcemic Disorders*. 291(20), 10876–10885. https://doi.org/10.1074/jbc.M115.696401
4.	Baiardi, S., Rossi, M., Mammana, A., Appleby, B. S., Barria, M. A., Calì, I., Gambetti, P., Gelpi, E., Giese, A., Ghetti, B., Herms, J., Ladogana, A., Mikol, J., Pal, S., Ritchie, D. L., Ruf, V., Windl, O., Capellari, S., & Parchi, P. (2021). Phenotypic diversity of genetic Creutzfeldt-Jakob disease: a histo-molecular-based classification. Acta Neuropathologica, 142(4), 707–728. https://doi.org/10.1007/s00401-021-02350-y
5.	Barbara Madoń, Eryk Mikos, Justyna Nowaczek, Martyna Wasyluk, & Natalia Wilczek. (2021). Prion diseases: fatal familial insomnia. Journal of Education, Health and Sport, 11(9), 29–36. https://doi.org/10.12775/JEHS.2021.11.09.004
6.	Baskakov, I. V., Legname, G., Prusiner, S. B., & Cohen, F. E. (2001). Folding of Prion Protein to Its Native α-Helical Conformation Is under Kinetic Control. Journal of Biological Chemistry, 276(23), 19687–19690. https://doi.org/10.1074/jbc.C100180200
7.	Bett, C., Joshi-Barr, S., Lucero, M., Trejo, M., Liberski, P., Kelly, J. W., Masliah, E., Sigurdson, C. J., & Mabbott, N. A. (2012). Biochemical Properties of Highly Neuroinvasive Prion Strains. PLoS Pathogens, 8(2). https://doi.org/10.1371/journal.ppat.1002522
8.	Cagiada, M., Johansson, K. E., Valanciute, A., Nielsen, S. V., Hartmann-Petersen, R., Yang, J. J., Fowler, D. M., Stein, A., Lindorff-Larsen, K., & Ozkan, B. (2021). Understanding the Origins of Loss of Protein Function by Analyzing the Effects of Thousands of Variants on Activity and Abundance. Molecular Biology and Evolution, 38(8), 3235–3246. https://doi.org/10.1093/molbev/msab095
9.	Chen, J., Vishweshwaraiah, Y. L., & Dokholyan, N. V. (2022). Design and engineering of allosteric communications in proteins. Current Opinion in Structural Biology, 73. https://doi.org/10.1016/j.sbi.2022.102334
10.	Choi, J.-K., Cali, I., Surewicz, K., Kong, Q., Gambetti, P., & Surewicz, W. K. (2016). Amyloid fibrils from the N-terminal prion protein fragment are infectious. Proceedings of the National Academy of Sciences of the United States of America, 113(48), 13851.
11.	Cistaro, A., Cassalia, L., Ferrara, C., Atzori, C., Vai, D., Quartuccio, N., Fania, P., Vaudano, G. P., & Imperiale, D. (2017). Brain 18F-FDG PET/CT findings in a case of genetic Creutzfeldt-Jakob disease due to V203I heterozygous mutation in the PRNP gene. Journal of Neurology, 264(1), 170–173. https://doi.org/10.1007/s00415-016-8327-5
12.	Delmotte, A., Tate, E. W., Yaliraki, S. N., & Barahona, M. (2011). Protein multi-scale organization through graph partitioning and robustness analysis: Application to the myosin-myosin light chain interaction. In arXiv.org (p. n). https://doi.org/10.1088/1478-3975/8/5/055010
13.	Diaz-espinoza, R., & Soto, C. (2012). High-resolution structure of infectious prion protein: the final frontier. Nature Structural & Molecular Biology, 19(4), 370–377. https://doi.org/10.1038/nsmb.2266
14.	Di Fede, G., Catania, M., Atzori, C., Moda, F., Pasquali, C., Indaco, A., Grisoli, M., Zuffi, M., Guaita, M. C., Testi, R., Taraglio, S., Sessa, M., Gusmaroli, G., Spinelli, M., Salzano, G., Legname, G., Tarletti, R., Godi, L., Pocchiari, M., et al. (2019). Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene. Acta Neuropathologica Communications, 7(1), 1–11. https://doi.org/10.1186/s40478-018-0656-4
15.	Ding, F., Dokholyan, N. V., & Shakhnovich, E. (2006). Emergence of Protein Fold Families through Rational Design. PLoS Computational Biology, 2(7). https://doi.org/10.1371/journal.pcbi.0020085
16.	Faure, A. J., Domingo, J., Schmiedel, J. M., Hidalgo-Carcedo, C., Diss, G., & Lehner, B. (2022). Mapping the energetic and allosteric landscapes of protein binding domains. Nature : International Weekly Journal of Science, 604(7904), 175–183. https://doi.org/10.1038/s41586-022-04586-4
17.	Friedrich, C. M. (2016). A model qualification method for mechanistic physiological QSP models to support model-informed drug development. CPT: Pharmacometrics & Systems Pharmacology, 5(2), 43–53. https://doi.org/10.1002/psp4.12056
18.	Gandoglia, Strada, Poleggi, Castaldi, Del Sette, & Di Maria. (2022). Penetrance of the V203I variant of the PRNP gene: report of a patient with stroke-like onset of Creutzfeld-Jacob Disease and review of published cases. Prion, 16(1), 19–22. https://doi.org/10.1080/19336896.2022.2035479
19.	Goncearenco, A., Mitternacht, S., Yong, T., Eisenhaber, B., Eisenhaber, F., & Berezovsky, I. N. (2013). SPACER: Server for predicting allosteric communication and effects of regulation. Nucleic Acids Research, 41(Web Server issue), W266–72. https://doi.org/10.1093/nar/gkt460
20.	Guarnera, E., & Berezovsky, I. N. (2016). Allosteric sites: remote control in regulation of protein activity. Current Opinion in Structural Biology, 37, 1–8. https://doi.org/10.1016/j.sbi.2015.10.004
21.	Guarnera, E., & Berezovsky, I. N. (2019). On the perturbation nature of allostery: sites, mutations, and signal modulation. Current Opinion in Structural Biology, 56, 18–27. https://doi.org/10.1016/j.sbi.2018.10.008
22.	Guarnera, E., & Berezovsky, I. N. (2019). Toward Comprehensive Allosteric Control over Protein Activity. Structure, 27(5), 866–878. https://doi.org/10.1016/j.str.2019.01.014
23.	Guarnera, E., Tan, Z. W., Zheng, Z., & Berezovsky, I. N. (2017). AlloSigMA: allosteric signaling and mutation analysis server. Bioinformatics, 33(24), 3996–3998. https://doi.org/10.1093/bioinformatics/btx430
24.	Guentchev, M., Wanschitz, J., Voigtländer, T., Flicker, H., & Budka, H. (1999). Selective neuronal vulnerability in human prion diseases. Fatal familial insomnia differs from other types of prion diseases. The American Journal of Pathology, 155(5), 1453–1457.
25.	Hu, J., Jiang, J., Costanzi, S., Thomas, C., Yang, W., Feyen, J. H. M., Jacobson, K. A., & Spiegel, A. M. (2006). A missense mutation in the seven-transmembrane domain of the human Ca2+ receptor converts a negative allosteric modulator into a positive allosteric modulator. The Journal of Biological Chemistry, 281(30), 21558–21565. https://doi.org/10.1074/jbc.M603682200
26.	Iwasaki, Y. (2017). Creutzfeldt-Jakob disease. Neuropathology, 37(2), 174–188. https://doi.org/10.1111/neup.12355
27.	Jeong, B.-H., Jeon, Y.-C., Lee, Y.-J., Cho, H.-J., Park, S.-J., Chung, D.-I., Kim, J., Kim, S. H., Kim, H.-T., Choi, E.-K., Choi, K.-C., Carp, R. I., & Kim, Y.-S. (2010). Creutzfeldt-Jakob disease with the V203I mutation and M129V polymorphism of the prion protein gene (PRNP) and a 17 kDa prion protein fragment. Neuropathology and Applied Neurobiology, 36(6), 558–563. https://doi.org/10.1111/j.1365-2990.2010.01094.x
28.	Lee, K.-H., & Kuczera, K. (2021). Free energy simulations to understand the effect of Met → Ala mutations at positions 205, 206 and 213 on stability of human prion protein. Biophysical Chemistry, 275. https://doi.org/10.1016/j.bpc.2021.106620
29.	Mitra, A., & Wang, Y. (2022). Applications of Model Informed Drug Development (MIDD) in Drug Development Lifecycle and Regulatory Review. Pharmaceutical Research : An Official Journal of the American Association of Pharmaceutical Scientists, 39(8), 1663–1667. https://doi.org/10.1007/s11095-022-03327-6
30.	Moda, F., Le, T.-N. T., Aulic, S., Bistaffa, E., Campagnani, I., Virgilio, T., Indaco, A., Palamara, L., Andréoletti, O., Tagliavini, F., & Legname, G. (2015). Synthetic prions with novel strain-specified properties. PLoS Pathogens, 11(12), n. https://doi.org/10.1371/journal.ppat.1005354
31.	Morales, R., Duran-Aniotz, C., Castilla, J., Estrada, L. D., & Soto, C. (2011). De novo induction of amyloid-β deposition in vivo. Molecular Psychiatry, 17(12), 1347–1353. https://doi.org/10.1038/mp.2011.120
32.	Mosca, R., Céol, A., & Aloy, P. (2013). Interactome3D: adding structural details to protein networks. Nature Methods, 10(1), 47–53. https://doi.org/10.1038/nmeth.2289
33.	Motlagh, H. N., Wrabl, J. O., Li, J., & Hilser, V. J. (2014). The ensemble nature of allostery. Nature : International Weekly Journal of Science, 508(7496), 331–339. https://doi.org/10.1038/nature13001
34.	Oakes, B. L., Nadler, D. C., Flamholz, A., Fellmann, C., Staahl, B. T., Doudna, J. A., & Savage, D. F. (2016). Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch. Nature Biotechnology, 34(6), 646–651. https://doi.org/10.1038/nbt.3528
35.	Parchi, P., de Boni, L., Saverioni, D., Cohen, M. L., Ferrer, I., Gambetti, P., Gelpi, E., Giaccone, G., Hauw, J.-J., Höftberger, R., Ironside, J. W., Jansen, C., Kovacs, G. G., Rozemuller, A., Seilhean, D., Tagliavini, F., Giese, A., & Kretzschmar, H. A. (2012). Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathologica : Pathology and Mechanisms of Neurological Disease, 124(4), 517–529. https://doi.org/10.1007/s00401-012-1002-8
36.	Patricia Soto, Garrett M. Gloeb, Kaitlin A. Tsuchida, Austin A. Charles, Noah M. Greenwood, & Heidi Hendrickson. (2023). Insight into the conserved structural dynamics of the C-terminus of mammal PrPC identifies structural core and possible structural role of pharmacological chaperones. Prion, 17(1), 55–66. https://doi.org/10.1080/19336896.2023.2186674
37.	Paweł P. Liberski, Agata Gajos, Beata Sikorska, & Shirley Lindenbaum. (2019). Kuru, the First Human Prion Disease. Viruses, 11(3), 232. https://doi.org/10.3390/v11030232
38.	Peoc’h, K., Guérin, C., Brandel, J. P., Launay, J. M., & Laplanche, J. L. (2000). First report of polymorphisms in the prion-like protein gene (PRND): implications for human prion diseases. Neuroscience Letters, 286(2), 144–148.
39.	Peoc’h, K., Manivet, P., Beaudry, P., Attane, F., Besson, G., Hannequin, D., Delasnerie-Lauprêtre, N., & Laplanche, J. L. (2000). Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Human Mutation, 15(5), 482.
40.	Rayman, J. B., & Kandel, E. R. (2017). Functional Prions in the Brain. Cold Spring Harbor Perspectives in Biology, 9(1). https://doi.org/10.1101/cshperspect.a023671
41.	Redler, R. L., Das, J., Diaz, J. R., & Dokholyan, N. V. (2016). Protein Destabilization as a Common Factor in Diverse Inherited Disorders. Journal of Molecular Evolution, 82(1), 11–16. https://doi.org/10.1007/s00239-015-9717-5
42.	Reynolds, K. A., McLaughlin, R. N., & Ranganathan, R. (2011). Hotspots for allosteric regulation on protein surfaces. Cell, 147(7), 1564–1575. https://doi.org/10.1016/j.cell.2011.10.049
43.	Sakaguchi, S. (2022). Prion Pathogenesis Revealed in a Series of the Special Issues “Prions and Prion Diseases”. International Journal of Molecular Sciences, 23(12), 6490. https://doi.org/10.3390/ijms23126490
44.	Sánchez-Valle, R. (2022). Prion diseases. European Neuropsychopharmacology, 55, 1–3. https://doi.org/10.1016/j.euroneuro.2021.09.008
45.	Schelzke, G., Stoeck, K., Eigenbrod, S., Grasbon-frodl, E., Raddatz, L. M., Ponto, C., Kretzschmar, H. A., & Zerr, I. (2013). Report about Four Novel Mutations in the Prion Protein Gene. Dementia and Geriatric Cognitive Disorders, 35(3-4), 229–237. https://doi.org/10.1159/000345991
46.	Takeuchi, A., Mohri, S., Kai, H., Tamaoka, A., Kobayashi, A., Mizusawa, H., Iwasaki, Y., Yoshida, M., Shimizu, H., Murayama, S., Kuroda, S., Morita, M., Parchi, P., & Kitamoto, T. (2019). Two distinct prions in fatal familial insomnia and its sporadic form. Brain Communications, 1(1), fcz045. https://doi.org/10.1093/braincomms/fcz045
47.	Tan, Z. W., Guarnera, E., Tee, W.-V., & Berezovsky, I. N. (2020). AlloSigMA 2: paving the way to designing allosteric effectors and to exploring allosteric effects of mutations. Nucleic Acids Research, 48(W1), W116–W124. https://doi.org/10.1093/nar/gkaa338
48.	Tan, Z. W., Tee, W.-V., Guarnera, E., & Berezovsky, I. N. (2023). AlloMAPS 2: allosteric fingerprints of the AlphaFold and Pfam-trRosetta predicted structures for engineering and design. Nucleic Acids Research, 51(D1), D345–D351. https://doi.org/10.1093/nar/gkac828
49.	Tee, W.-V., Guarnera, E., & Berezovsky, I. N. (2019). On the Allosteric Effect of nsSNPs and the Emerging Importance of Allosteric Polymorphism. Journal of Molecular Biology, 431(19), 3933–3942. https://doi.org/10.1016/j.jmb.2019.07.012
50.	Verkhivker, G. M. (2021). Making the invisible visible: Toward structural characterization of allosteric states, interaction networks, and allosteric regulatory mechanisms in protein kinases. Current Opinion in Structural Biology, 71, 71–78. https://doi.org/10.1016/j.sbi.2021.06.002
51.	Volpicelli-Daley, L., Luk, K., Patel, T., Tanik, S., Riddle, D., Stieber, A., Meaney, D., Trojanowski, J., & Lee, V.-Y. (2011). Exogenous [alpha]-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death. Neuron, 72(1), 57–71. https://doi.org/10.1016/j.neuron.2011.08.033
52.	Wadsworth, J. D. F., Joiner, S., Linehan, J. M., Desbruslais, M., Fox, K., Cooper, S., Cronier, S., Asante, E. A., Mead, S., Brandner, S., Hill, A. F., & Collinge, J. (2008). Kuru prions and sporadic Creutzfeldt-Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proceedings of the National Academy of Sciences, 105(10), 3885–3890. https://doi.org/10.1073/pnas.0800190105
53.	Wang, J., Jain, A., McDonald, L. R., Gambogi, C., Lee, A. L., & Dokholyan, N. V. (2020). Mapping allosteric communications within individual proteins. Nature Communications, 11(1), 3862. https://doi.org/10.1038/s41467-020-17618-2
54.	Yin, S., Ding, F., & Dokholyan, N. V. (2007). Modeling backbone flexibility improves protein stability estimation. Structure (London, England : 1993), 15(12), 1567–1576.
55.	Zahn, R., Liu, A., Luhrs, T., & Riek, R. (1999). NMR solution structure of the human prion protein. Proceedings of the National Academy of Sciences of the United States of America, 97(1), 145–150.
56.	Zanusso, G., Fiorini, M., Ferrari, S., Meade-White, K., Barbieri, I., Brocchi, E., Ghetti, B., & Monaco, S. (2014). Gerstmann-Sträussler-Scheinker Disease and “Anchorless Prion Protein” Mice Share Prion Conformational Properties Diverging from Sporadic Creutzfeldt-Jakob Disease*. 289(8), 4870–4881. https://doi.org/10.1074/jbc.M113.531335
57.	Zhang, Q., Zhang, H., Zheng, F., Liu, R., Liao, X., Guo, C., & Lin, D. (2021). 1H, 13C, 15N backbone and side‐chain resonance assignments of the pathogenic G131V mutant of human prion protein (91–231). Biomolecular NMR Assignments, 15(2), 311–316. https://doi.org/10.1007/s12104-021-10022-x
58.	Zheng, Z., Zhang, M., Wang, Y., Ma, R., Guo, C., Feng, L., Wu, J., Yao, H., & Lin, D. (2018). Structural basis for the complete resistance of the human prion protein mutant G127V to prion disease. Scientific Reports, 8(1), 13211. https://doi.org/10.1038/s41598-018-31394-6
